about
Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy.Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysisAdherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study.Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South AfricaConcordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.Discontinuation of cART postpartum in a high prevalence district of South Africa in 2014.Cardiac arrest and cardiopulmonary resuscitation outcome reports: update and simplification of the Utstein templates for resuscitation registries: a statement for healthcare professionals from a task force of the International Liaison Committee on RPlasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimenEffect of Maternal HIV-1 Status and Antiretroviral Drugs on Haematological Profiles of South African Infants in Early Life.Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in childrenSex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational studyAbsence seizures associated with efavirenz initiationCase report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy.Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed.Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis.Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trialReuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.Cardiac arrest and cardiopulmonary resuscitation outcome reports: update and simplification of the Utstein templates for resuscitation registries. A statement for healthcare professionals from a task force of the international liaison committee on rHIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine"I get hungry all the time": experiences of poverty and pregnancy in an urban healthcare setting in South Africa.The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy.Efavirenz is associated with higher bone mass in South African children with HIV.Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical TrialIntegration of antiretroviral treatment within antenatal care in Gauteng Province, South Africa.Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.Adherence and viral suppression among infants and young children initiating protease inhibitor-based antiretroviral therapy.Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virusDecreased Vigorous Physical Activity in School-Aged Children with Human Immunodeficiency Virus in Johannesburg, South Africa.Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected ChildrenExtent of disclosure: what perinatally HIV-infected children have been told about their own HIV status.Timing of maternal HIV testing and uptake of prevention of mother-to-child transmission interventions among women and their infected infants in Johannesburg, South Africa.
P50
Q33605245-17EF50DF-A855-4C30-97D9-1BFE2CFCA145Q33605273-F9D1DFB0-BD64-4BBA-9AEF-AB2A78DEF46FQ33624953-5981666C-F185-46D9-BA8A-4E112BF171B6Q33814942-19B98F7F-4196-4F28-91AD-FF42900ABCC9Q33839294-E1D8FD70-4E04-44E2-8130-79E60C510296Q33893057-729BF260-E6B5-4AAD-B5D7-70657E7A8843Q34112568-129AC63A-2D85-4973-AB4D-380E92C28769Q34159649-5439DC1A-F098-4665-929C-8CC268359C1CQ34346828-D7615D2B-8F20-46B5-B54D-69D0EAC2A548Q34370176-D91FD7E4-CCCB-40A5-A6D7-8624BAC311F6Q34498914-1923C49E-0451-4E69-86C7-3D8C41C4F3E0Q34508373-90753437-8B7D-4E50-9096-29DEA92A34E6Q34699162-1ACCCA55-5565-420E-8CC8-783801C72D30Q35093189-515F3348-DD53-4782-942B-42DE5C7B82C1Q35179391-41706D12-FB32-40E7-8B55-818BB000168CQ35184921-5727BF4B-6415-4293-BB24-5BBC6E946556Q35752638-C70BDA3E-B970-4EE9-86FB-3397E4F8151CQ35910664-F2954282-6A2B-4B24-A69B-5195F53F71F8Q35926011-98AB1738-28F8-4CC5-A26E-D5B81AC6972CQ35942373-74BFDC51-B186-497E-B20E-737779151B55Q35945312-35FC3CFC-335A-4CB0-AFC3-A487CCF58DE3Q35962423-5FB920BD-9E0C-46B6-B2CF-6CDDFBD78463Q35965344-54E4769C-65ED-4545-91EE-03D5FD42A1C7Q35965440-F0AA8FAD-6DF0-4987-9753-B38FDA66274EQ35965722-9228B507-7161-4F0B-9A15-CA6835A70521Q35975289-A690BAA4-4B9A-4915-9322-73DB2B443425Q35990257-70984AD1-59BC-42EE-820E-F32AC7A42E47Q35995278-3F67AC73-D0F7-46F7-89F0-D3B51413CFDCQ36032235-A573B32D-E28C-4083-BA21-035117D9E0B4Q36079798-593FAE80-8953-4CC8-B14B-92FD318C4F7CQ36306986-70E2D0FA-4F9F-41C9-861E-377520999063Q36619232-CC8DFEC5-971F-4F47-8880-1B0276D0EA1FQ36729996-FA91A1AD-5DE4-4CA0-BA96-0FD52E7E3954Q36759507-D6037D71-E0E9-43EE-AF53-67DF249044B8Q36807963-33100760-C212-46C8-9CAD-3FB573739F6AQ36839977-3203AACB-0A7E-4EBC-95FD-2B4A152F56F1Q37029110-405B3C6B-5E52-4DB8-AABD-BC2F206638DAQ37513856-4D2683FF-A307-46D4-915F-E27DAB69DD47Q37653305-0AFC8D4F-94F2-4EED-BEAE-95FEC1D23A14Q37723043-D3465A47-1786-4579-9BC4-1B4B26C0B56C
P50
name
Ashraf Coovadia
@en
type
label
Ashraf Coovadia
@en
prefLabel
Ashraf Coovadia
@en